• Paths of Progress Fall/Winter 2011

    Pinpointing Weaknesses in Cancer's Genetic Code

    By Robert Levy

    "We can use this technology to extract highly relevant information from tumors that may guide future treatment choices or foster the development of new therapies."
    – Levi Garraway, MD, PhD
    Co-developer of OncoMap

    At the heart of the new genetic screening research program at Dana-Farber and Brigham and Women's Hospital is OncoMap, a system that scans patients' tumor tissue for gene mutations involved in cancer. Information generated by OncoMap will provide a treasury of data for research into the genetic connection between tumors and their response to therapy.

    Developed by scientists at Dana-Farber and the Broad Institute of MIT and Harvard, OncoMap is able to scan large numbers of tumor samples at a reasonable cost – a key prerequisite for a research project open to as many patients as wish to participate. The system is taking its place alongside the pathologist's microscope as a tool for categorizing cancers and investigating novel treatments.

    OncoMap_1 OncoMap_2

    Paths of Progress Fall/Winter 2011 Table of Contents 

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms